Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABSI NYSE:MRK NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABSIAbsci$10.23+0.1%$7.52$2.24▼$12.06$1.59B2.324.76 million shs449,299 shsMRKMerck & Co., Inc.$120.86-2.6%$119.12$76.66▼$130.29$298.55B0.1910.95 million shs1.41 million shsRXRXRecursion Pharmaceuticals$3.23-2.3%$3.34$2.77▼$7.18$1.70B118.26 million shs6.47 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABSIAbsci-3.11%-11.01%+51.03%+226.03%+284.64%MRKMerck & Co., Inc.+0.17%-2.25%+4.10%+3.33%+48.69%RXRXRecursion Pharmaceuticals-7.30%-16.67%+4.76%-6.78%-37.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABSIAbsci$10.23+0.1%$7.52$2.24▼$12.06$1.59B2.324.76 million shs449,299 shsMRKMerck & Co., Inc.$120.86-2.6%$119.12$76.66▼$130.29$298.55B0.1910.95 million shs1.41 million shsRXRXRecursion Pharmaceuticals$3.23-2.3%$3.34$2.77▼$7.18$1.70B118.26 million shs6.47 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABSIAbsci-3.11%-11.01%+51.03%+226.03%+284.64%MRKMerck & Co., Inc.+0.17%-2.25%+4.10%+3.33%+48.69%RXRXRecursion Pharmaceuticals-7.30%-16.67%+4.76%-6.78%-37.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABSIAbsci 2.78Moderate Buy$13.4331.33% UpsideMRKMerck & Co., Inc. 2.70Moderate Buy$133.9410.82% UpsideRXRXRecursion Pharmaceuticals 2.20Hold$8.10151.16% UpsideCurrent Analyst Ratings BreakdownLatest ABSI, MRK, and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026MRKMerck & Co., Inc. JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$135.00 ➝ $140.007/13/2026MRKMerck & Co., Inc. BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$135.00 ➝ $142.007/13/2026MRKMerck & Co., Inc. GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$140.00 ➝ $145.007/9/2026MRKMerck & Co., Inc. Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$112.00 ➝ $113.007/8/2026MRKMerck & Co., Inc. Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$142.007/8/2026MRKMerck & Co., Inc. Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$145.00 ➝ $150.007/6/2026MRKMerck & Co., Inc. Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$120.007/2/2026ABSIAbsci Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $17.006/30/2026MRKMerck & Co., Inc. Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$130.00 ➝ $141.006/30/2026MRKMerck & Co., Inc. ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Outperform$136.00 ➝ $155.006/25/2026ABSIAbsci Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingPositive$10.00(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABSIAbsci$2.80M569.31N/AN/A$1.26 per share8.12MRKMerck & Co., Inc.$65.01B4.59$11.18 per share10.81$21.22 per share5.70RXRXRecursion Pharmaceuticals$74.68M22.88N/AN/A$2.14 per share1.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABSIAbsci-$115.18M-$0.83N/AN/AN/A-6,450.76%-66.32%-57.01%8/11/2026 (Estimated)MRKMerck & Co., Inc.$18.25B$3.5534.0512.212.6513.59%27.55%10.73%8/4/2026 (Estimated)RXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%8/4/2026 (Estimated)Latest ABSI, MRK, and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026ABSIAbsci-$0.15N/AN/AN/A$0.89 millionN/A8/4/2026Q2 2026MRKMerck & Co., Inc.$2.15N/AN/AN/A$16.40 billionN/A8/4/2026Q2 2026RXRXRecursion Pharmaceuticals-$0.25N/AN/AN/A$11.20 millionN/A5/7/2026Q1 2026ABSIAbsci-$0.20-$0.19+$0.01-$0.19$1.39 million$0.22 million5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 million4/30/2026Q1 2026MRKMerck & Co., Inc.-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABSIAbsciN/AN/AN/AN/AN/AMRKMerck & Co., Inc.$3.402.81%+5.75%95.77%14 YearsRXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ALatest ABSI, MRK, and RXRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/26/2026MRKMerck & Co., Inc.quarterly$0.852.96%6/15/20266/15/20267/8/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABSIAbsciN/A6.596.59MRKMerck & Co., Inc.1.021.301.06RXRXRecursion Pharmaceuticals0.015.475.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABSIAbsci52.05%MRKMerck & Co., Inc.76.07%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipABSIAbsci10.52%MRKMerck & Co., Inc.0.17%RXRXRecursion Pharmaceuticals6.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABSIAbsci210155.90 million139.50 millionOptionableMRKMerck & Co., Inc.75,0002.47 billion2.47 billionOptionableRXRXRecursion Pharmaceuticals400529.91 million494.67 millionOptionableABSI, MRK, and RXRX HeadlinesRecent News About These CompaniesCathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?2 hours ago | fool.comInsider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $158,400.00 in StockJuly 12 at 11:08 AM | americanbankingnews.com2 Beaten-Down Stocks That Still Aren't Worth BuyingJuly 11 at 6:46 PM | fool.comHsbc Holdings PLC Grows Position in Recursion Pharmaceuticals, Inc. $RXRXJuly 11 at 8:23 AM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 7.8% on Insider SellingJuly 10, 2026 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Rating of "Hold" by BrokeragesJuly 10, 2026 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 40,000 SharesJuly 9, 2026 | marketbeat.comIs Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires?July 9, 2026 | finance.yahoo.comHere's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader MarketJuly 8, 2026 | finance.yahoo.comHere's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader MarketJuly 8, 2026 | zacks.com3 Cancer Stocks to Watch as Oncology Innovation AcceleratesJuly 8, 2026 | zacks.com5 Best Penny Stocks to Invest In According to BillionairesJuly 7, 2026 | insidermonkey.comRecursion Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug HopesJuly 5, 2026 | finance.yahoo.comRecursion Pharmaceuticals (RXRX) Is Up 8.0% After Russell Index Additions Expand Its Investor Base – Has The Bull Case Changed?July 5, 2026 | finance.yahoo.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from BrokeragesJuly 5, 2026 | marketbeat.comDyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?July 4, 2026 | fool.comModerna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?July 3, 2026 | fool.comInvestors Purchase Large Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)July 1, 2026 | marketbeat.comShort interest alert: Most and least shorted sub-$2B healthcare stocks in June 2026July 1, 2026 | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 8.5% - Should You Buy?July 1, 2026 | marketbeat.comRecursion Pharmaceuticals, Inc. $RXRX Shares Acquired by Hsbc Holdings PLCJune 29, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABSI, MRK, and RXRX Company DescriptionsAbsci NASDAQ:ABSI$10.24 +0.03 (+0.25%) As of 10:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.Merck & Co., Inc. NYSE:MRK$120.72 -3.31 (-2.67%) As of 10:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.Recursion Pharmaceuticals NASDAQ:RXRX$3.22 -0.08 (-2.27%) As of 10:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Baggage Claim: Apollo’s $7.7 Billion Bid to Acquire easyJet The SK Hynix IPO and 2027’s AI Memory Squeeze Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain Fission for Profits: Unlocking America’s Uranium Vault The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
